Maybe it dips to the 3's, but maybe not. For the first time in many years, in this CC we learned of relatively near-term products that can propel Elite's revenue higher, possibly much higher. These are the very near-term submission of Oxy generic and the existence of 3 'needle' moving products coming up in the next year or two. We haven't had clear direction on any 'big' products (big as in lots of revenue potential) other than we had some in the early development cycle. There was zero motivation for anyone to invest because there wasn't anything we knew about in the pipeline that could improve revenue. The market is forward looking but it has to have something concrete to bet on. Finally we do.
News 
Market Data 
Discover 
